10 minutes read
Relapsed and refractory (r/r) hematologic malignancies — hematologic cancers that have progressed despite first-line treatment or remain uncontrolled after second or third-line therapy — have historically been the patient group with the worst prognosis. But over the past 5 years, the emergence of breakthrough therapies — CAR-T, bispecific antibodies, novel small molecule targeted drugs, and haploidentical HSCT sequential strategies — has substantially changed r/r hematologic disease outcomes. China is among the global providers of these therapies — with 6 NMPA-approved CAR-T products, multiple approved bispecific antibodies, the Beijing Protocol haploidentical HSCT allowing patients without HLA-matched donors to receive transplant, and pricing approximately 1/3 to 1/10 of US costs. This article provides a complete treatment pathway in China for r/r hematologic disease patients — organized by disease, including sequential strategies, and practical access pathways.
The Special Challenge of Relapsed and Refractory Hematologic Malignancies
Why r/r patients are harder to treat than newly diagnosed:
- Resistance: tumor clones surviving first-line treatment typically have resistance mechanisms
- Disease progression: after multi-line treatment failure, tumor burden is often larger and more disseminated
- Normal hematopoietic system damage: cumulative damage to bone marrow from multi-line chemotherapy
- Organ function decline: long-term treatment effects on liver, kidney, cardiac function
- Quality of life decline: reduced performance status, malnutrition, psychological burden
Practical implication for patients: r/r treatment requires a complete multi-modality strategy — single drugs or single treatments rarely deliver durable remission. China’s advantage is providing simultaneous access to CAR-T, bispecific antibodies, HSCT, and other modern treatments, with substantial pricing advantages that make long-term sequential treatment economically feasible.
China-Available Treatment Options by Disease
1. Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL)
China-available options:
CAR-T (see Article 21):
- Axi-cel (Yescarta, Fosun Kite) — NMPA approved June 2021
- Relma-cel (Carteyva, JW Therapeutics) — NMPA approved September 2021
- A complete CAR-T course in China is approximately $160K–$220K USD (see Article 21)
Bispecific antibodies:
- Glofitamab (Roche Columvi) — NMPA approved November 2023 [1]
- Used for patients with relapsed/refractory DLBCL who have received at least 2 lines of systemic therapy
- Advantage over CAR-T: off-the-shelf product (immediate use, no individualized manufacturing wait)
Other options:
- BTK inhibitors (especially for MYD88 / CD79B mutation subtypes)
- Anti-CD20 + chemotherapy reinduction
- Autologous HSCT (specific indications)
Typical treatment pathway decisions:
| Patient Situation | Recommended Pathway |
|---|---|
| 2nd-line failure + good performance status | CAR-T (first choice) or glofitamab (if unable to wait for CAR-T manufacturing) |
| Multi-line failure + poor performance status | Glofitamab off-the-shelf (no manufacturing wait) |
| Post-CAR-T relapse | Glofitamab or clinical trial |
2. Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-ALL)
China-available options:
- Inaticabtagene autoleucel CAR-T (CASI Pharma) — NMPA approved November 2023, China’s first B-ALL CAR-T (see Article 21)
- Blinatumomab (bispecific T-cell engager) — adult NMPA approved December 2020, pediatric May 2022 [2]
- Beijing Protocol haploidentical HSCT — see Article 24, allowing parents/children as donors
- Bridging to HSCT after treatment is a common strategy
Typical sequential pathway:
- CAR-T or blinatumomab achieves deep remission
- Sequential haploidentical HSCT for consolidation
- Zhejiang 1st Hospital Huang He team NEJM 2024 data: CD7 CAR-T + allogeneic HSCT sequential (no GVHD prophylaxis), 10 r/r T-ALL/LBL patients, 1-year OS 68% [3]
3. Relapsed/Refractory Acute Myeloid Leukemia (r/r AML)
China-available options:
- Venetoclax (BCL2 inhibitor) + azacitidine / decitabine — venetoclax conditionally NMPA approved December 2020 [4]
- China’s only approved BCL2 inhibitor
- Suitable for elderly or frail patients unsuitable for intensive chemotherapy
- Beijing Protocol haploidentical HSCT — core curative therapy
- Some r/r AML patients can enroll in NK cell therapy or novel CAR-T clinical trials
Typical treatment pathway decisions:
| Patient Situation | Recommended Pathway |
|---|---|
| Good performance + suitable donor | Intensive reinduction → allo-HSCT |
| Poor performance or elderly | Venetoclax + hypomethylating agent |
| Multi-line failure + awaiting transplant | Venetoclax bridge to HSCT |
4. Relapsed/Refractory Multiple Myeloma (r/r MM)
China-available options (after ≥3 prior lines of treatment):
BCMA CAR-T (China has 3 NMPA-approved, see Article 21):
- Equecabtagene autoleucel (IASO/Innovent, June 2023)
- Zevor-cel (CARsgen, March 2024)
- Cilta-cel (Legend/Johnson & Johnson, August 2024)
Teclistamab (BCMA × CD3 bispecific antibody):
- NMPA approved June 2024 [5]
- Off-the-shelf product, immediate use
- For r/r MM after at least 3 prior lines of treatment
Other availability:
- Second-generation proteasome inhibitors (carfilzomib)
- Immunomodulatory drugs (lenalidomide, pomalidomide)
- Daratumumab (CD38 monoclonal antibody)
- Selinexor (XPO1 inhibitor)
Typical treatment pathways:
| Patient Situation | Recommended Pathway |
|---|---|
| 3rd-line failure + suitable for CAR-T | BCMA CAR-T (best deep remission) |
| Unable to wait for CAR-T manufacturing | Teclistamab bispecific as bridge |
| Post-CAR-T relapse | Teclistamab or daratumumab re-challenge |
5. Relapsed/Refractory Hodgkin Lymphoma (r/r HL)
China-available options:
- Brentuximab vedotin (Adcetris) ADC — NMPA approved May 2020 for CD30+ HL/sALCL [6]
- PD-1 inhibitors — multiple Chinese domestic PD-1 drugs have NMPA-approved r/r HL indications (see Article 27)
- Autologous HSCT — standard consolidation for HL relapse after first-line chemotherapy
- Allogeneic HSCT — curative option after multi-line failure
Typical treatment pathway:
- PD-1 ± brentuximab vedotin to achieve remission
- Autologous HSCT for consolidation
- Multi-line failure: allogeneic HSCT
6. Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)
China-available options:
- Relma-cel CAR-T — NMPA added MCL indication August 2024 [7]
- BTK inhibitors (zanubrutinib, orelabrutinib, acalabrutinib — see Article 27)
- Venetoclax (selected cases)
- Autologous HSCT
China’s Unique Advantages in r/r Treatment
Advantage 1 · Beijing Protocol Haploidentical HSCT
See Article 24 — allowing parents, children, and siblings to serve as donors, this is the key curative option for r/r hematologic patients without HLA-matched donors.
Advantage 2 · CAR-T + HSCT Sequential Strategy
China leads internationally in “CAR-T bridge to HSCT” strategy [3]:
- HSCT performed immediately after CAR-T achieves deep remission
- Substantially reduces relapse rates
- Zhejiang 1st Hospital Huang He team 2024 NEJM CD7 CAR-T + alloHSCT data is the international benchmark
Advantage 3 · “Off-the-Shelf” Value of Bispecific Antibodies
CAR-T requires 10–14 days of individualized manufacturing — for rapidly progressing patients, this wait may not be feasible. Bispecific antibodies (glofitamab, teclistamab, blinatumomab) are off-the-shelf products — they can serve as bridging therapy while waiting for CAR-T manufacturing.
Advantage 4 · Pricing Makes Long-Term Sequential Treatment Feasible
r/r hematologic disease typically requires multi-line sequential treatment (CAR-T + HSCT + long-term immunosuppression + maintenance therapy, etc.). China’s overall pricing is approximately 1/3–1/10 of US — making long-term treatment economically sustainable.
China’s Leading r/r Hematologic Disease Centers
(Detailed introductions in Articles 21 and 24)
- Peking University People’s Hospital Hematology (Academician Huang Xiaojun / Professor Zhang Xiaohui Team) — Beijing Protocol haploidentical HSCT global leader
- Zhejiang University 1st Affiliated Hospital (Professor Huang He Team) — CD7 CAR-T + alloHSCT NEJM 2024
- Soochow University 1st Affiliated Hospital (Professor Wu Depei) — National Clinical Research Center for Hematologic Disorders + ASHI-accredited high-resolution HLA laboratory
- Institute of Hematology and Blood Diseases Hospital (Tianjin) — national hematologic Tier-3A specialty hospital
- Shanghai Ruijin Hospital Hematology (Professor Zhao Weili Team) — strong in lymphoma targeted therapy
- Peking Union Medical College Hospital Hematology — strong comprehensive capability
International Patient Pathway for r/r Hematologic Treatment in China
Best-suited international patient profile:
- First- or second-line treatment failure in home country, with established r/r diagnosis
- Long CAR-T waiting time in home country (particularly Europe, often months)
- CAR-T or HSCT pricing unaffordable in home country
- No suitable HLA-matched HSCT donor in home country — Beijing Protocol allows parents/children as donors
- China-available bispecific antibodies or novel drugs not approved in home country
Typical time in China:
| Treatment | Time in China |
|---|---|
| CAR-T (see Article 21) | 6–9 weeks |
| Haploidentical HSCT (see Article 24) | 10–14 weeks |
| CAR-T + HSCT sequential | 12–20 weeks |
| Bispecific antibody course | 6–12 weeks (plan-dependent) |
Practical steps (synthesized):
- Remote second opinion evaluation (Article 9) — determine which treatment best fits
- MDT consultation (Article 10) — hematology + oncology + transplant joint planning
- Complete records preparation (Article 7) — especially pathology slides (Article 19) and genetic testing results
- Arrive in China + treatment + long-term remote follow-up after return
Common Questions
My DLBCL relapsed after CAR-T at home — what can China still offer? Glofitamab (China NMPA approved November 2023) is the primary option after CAR-T failure. Other options include a different CAR-T product, clinical trial combination drugs, etc.
I don’t have a matched HSCT donor — can Beijing Protocol really let my parents donate? Yes (see Article 24). The core breakthrough of Beijing Protocol is enabling haploidentical (half-match) donors to perform transplant — your parents, children (100% half-matched), and siblings (50% probability of half-matching) may be potential haploidentical donor sources, but eligibility requires HLA, health, infection and ethics screening; reported outcomes in specific studies and centers can approach those of matched transplants but cannot be generalized to all patients.
CAR-T or HSCT — which first? For most r/r ALL and r/r MM patients, CAR-T first to achieve deep remission, then bridge to HSCT consolidation is currently the optimal strategy. Specific sequencing requires MDT evaluation.
What options remain for elderly r/r AML patients? Venetoclax + azacitidine / decitabine is the first choice — achieving remission without intensive chemotherapy; some patients can bridge to HSCT.
What’s the advantage of bispecific antibodies over CAR-T? Off-the-shelf product + immediate use — no 10-14 day individualized manufacturing wait; outpatient or short hospital stay administration — shorter than the CAR-T inpatient monitoring period; can be repeated — CAR-T is typically a one-time treatment.
Roughly how much does r/r hematologic treatment in China cost?
- CAR-T single course approximately $160K–$220K USD
- Haploidentical HSCT approximately $50K–$80K USD
- Bispecific antibody course + long-term maintenance requires specific assessment
- Overall approximately 1/3 to 1/10 of US
Can long-term follow-up after r/r treatment be done after returning home? Yes. The critical step is establishing immediate post-treatment coordination with your home country hematology / transplant center — MedCareInChina facilitates remote coordination. Most r/r hematologic treatments require ≥2 years of long-term follow-up.
Bottom Line
Core value of r/r hematologic disease treatment in China:
- Multiple modern treatments simultaneously accessible: CAR-T, bispecific antibodies, haploidentical HSCT, novel targeted drugs
- Beijing Protocol enables transplant for patients without matched donors
- CAR-T + HSCT sequential strategy internationally leading (Zhejiang 1st NEJM 2024)
- Pricing advantages make long-term sequential treatment economically feasible
Best-suited international patients:
- r/r DLBCL, r/r B-ALL, r/r AML, r/r MM, r/r HL, r/r MCL
- Long CAR-T waiting time or unaffordable cost in home country
- No HLA-matched HSCT donor, wanting to use Beijing Protocol haploidentical approach
- Need home country-unapproved bispecific antibodies (such as teclistamab, glofitamab)
Total time in China: 6–20 weeks (depending on treatment combination)
If you or a family member has r/r hematologic disease, MedCareInChina matches the most appropriate Chinese hematology center and treatment sequence based on your specific diagnosis, prior treatment, and genetic testing results — and clearly identifies expected timeline, estimated cost, and long-term management pathway.
Start with a free Pathway Scan. We will tell you whether China is worth further consideration and which type of next step may fit. The free scan does not include hospital or doctor recommendations, medical advice, individualized cost estimates, insurance determinations, or treatment planning.
See Service & Refund Policy and Medical Disclaimer for service boundaries.
Sources
- Glofitamab China NMPA approval — Roche Columvi, November 2023 NMPA approval for r/r DLBCL. Source: https://www.ainvest.com/news/roche-glofitamab-approved-china-relapsed-lymphoma-2505/
- Blinatumomab China NMPA approval — Adult December 2020, pediatric May 2022. Source: https://www.businesswire.com/news/home/20201207005670/en/
- Zhejiang 1st CD7 CAR-T + alloHSCT sequential (NEJM 2024) — Huang H, et al. NEJM April 2024. 10 r/r CD7+ T-ALL/LBL patients, 1-year OS 68%, DFS 54%. Sources: https://www.nejm.org/doi/pdf/10.1056/NEJMoa2313812 ; https://pubmed.ncbi.nlm.nih.gov/38657244/
- Venetoclax China NMPA approval — December 2020 conditional approval for CLL and AML (combined with azacitidine / decitabine). Sources: https://news.abbvie.com/2020-10-16- ; https://pmc.ncbi.nlm.nih.gov/articles/PMC10149010/
- Teclistamab China NMPA approval — June 2024 NMPA approval for r/r MM. Source: https://www.medthority.com/news/2024/6/nmpa-china-approves-tecvayli-
- Brentuximab vedotin (Adcetris) China NMPA approval — May 2020 NMPA approval for CD30+ HL/sALCL. Source: Takeda China https://www.takeda.com/newsroom/newsreleases/2020/
- Relma-cel MCL indication — NMPA added MCL indication August 2024. Source: Lymphoma Hub https://lymphomahub.com/medical-information/relmacabtagene-autoleucel-receives-china-nmpa-supplementary-biological-application-approval-for-rr-mcl
- Beijing Protocol Haploidentical HSCT — Peking University People’s Hospital Academician Huang Xiaojun. Covers more than half of global haploidentical transplant cases, 3-year OS increased from ~20% to ~70%. Sources: https://pubmed.ncbi.nlm.nih.gov/31431695/ ; PKU news https://newsen.pku.edu.cn/news_events/news/people/13991.html
- Soochow University 1st Affiliated Hospital Hematology Institute — National Clinical Research Center for Hematologic Disorders, ASHI-accredited HLA laboratory. Source: China Daily https://govt.chinadaily.com.cn/s/201904/23/WS5cbeb6dd498e079e6801ec4d/
- Institute of Hematology and Blood Diseases Hospital (Tianjin) — CAMS&PUMC’s only national hematologic Tier-3A specialty hospital. Source: https://en.wikipedia.org/wiki/Institute_of_Hematology_and_Blood_Diseases_Hospital,CAMS%26_PUMC
